Copy For Citation
Tanriover M. D., Doganay H. L., AKOVA M., GÜNER H. R., Azap A., AKHAN S., ...More
LANCET, vol.398, no.10296, pp.213-222, 2021 (SCI-Expanded)
-
Publication Type:
Article / Article
-
Volume:
398
Issue:
10296
-
Publication Date:
2021
-
Doi Number:
10.1016/s0140-6736(21)01429-x
-
Journal Name:
LANCET
-
Journal Indexes:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, Aquatic Science & Fisheries Abstracts (ASFA), BIOSIS, CAB Abstracts, EMBASE, Food Science & Technology Abstracts, MEDLINE, Psycinfo, Veterinary Science Database
-
Page Numbers:
pp.213-222
-
Karadeniz Technical University Affiliated:
Yes
Abstract
Background CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years and older in phase 1/2 trials, and provided a good humoral response against SARS-CoV-2. We present the interim efficacy and safety results of a phase 3 clinical trial of CoronaVac in Turkey.